10月29日，Hims & Hers Health Inc.盘中上涨5.19%，报29.36美元/股，成交额1.64亿美元。
消息面上，公司此前请求加州联邦法官驳回联邦贸易委员会投诉。该投诉指称公司曾就产品误导消费者，并对不需要的订阅收费，相关司法进展成为近期市场关注点。
在此之前，公司还持续推进业务扩张，包括在澳大利亚推出Hers女性健康平台，并上线每周两次的睾酮增加皮下注射剂，显示其在国际化与新品布局上仍保持推进。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.